Gatuzosiran vs Rapirosiran (ALN-HSD)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

MASH / NASH

Shared mechanism: HSD17B13 · full MASH / NASH pipeline

Gatuzosiran

Developed by GlaxoSmithKline and partners

Phase 2 in MASH / NASHRNAi (siRNA)
Weak signal

NCT06104319 · Phase 2 · completed

The trial randomized participants among four GSK4532990 dose groups, but it was open-label, had no placebo or active comparator, and used biomarker expression rather than a clinical or endoscopic outcome as its primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Predicted percent change from baseline in liver biopsy-derived HSD17B13 protein expression levels (Baseline (Day 1) and up to Week 28): Predicted mean change from baseline in HSD17B13 protein expression at Week 28: -26.82% (25 mg), -61.82% (200 mg), -70.02% (400 mg), -75.27% (800 mg)

Result source: NCT06104319

Rapirosiran (ALN-HSD)

Developed by Regeneron Pharmaceuticals and partners

Phase 2 in MASH / NASHRNAi (siRNA)
Weak signal

NCT04565717 · Phase 1 · terminated

This randomized, double-blind, placebo-controlled Phase 1 study (ALN-HSD-001) gave single ascending doses of rapirosiran (ALN-HSD) or placebo to 58 healthy adults and two doses 12 weeks apart to 46 adults with MASH. Its primary endpoint was the frequency of adverse events, with no efficacy hypothesis, so there is no met or missed result. There were no treatment-related serious adverse events and no drug-induced liver injury, and liver HSD17B13 mRNA fell by a median 78% at 6 months at the highest dose. The registry lists only 6 participants and posts no results; the figures come from the peer-reviewed paper (J Hepatol 2025), which names this registration.

The registry lists 6 participants (terminated) and posts no results; the published paper (J Hepatol 2025, PMID 40581300) reports 58 healthy adults in Part A and 46 adults with MASH in Part B.

Next expected readout: April 2028 · NCT05519475 (registry estimate)

Reported efficacy

Parts A and B: Frequency of Adverse Events (Part A: Up to 3.5 months; Part B: up to 12.5 months); Part C: Change from Baseline of Liver Hydroxysteroid 17β Dehydrogenase 13 (HSD17B13) Messenger Ribonucleic Acid (mRNA) (Baseline and Month 6): Primary outcome, safety (no formal efficacy test): no treatment-related serious adverse events and no evidence of drug-induced liver injury in Part A (58 healthy adults) or Part B (46 adults with MASH). Secondary: dose-dependent reduction in liver HSD17B13 mRNA, median 78% at 6 months at 400 mg (J Hepatol 2025). (not_applicable)

Result source: NCT04565717

Results for MASH / NASH

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGatuzosiranRapirosiran (ALN-HSD)
MASH resolution without fibrosis worsening—Not reported—Not reported
Fibrosis stage, change—Not reported—Not reported
Liver fat (MRI-PDFF), change—Not reported—Not reported
ALT, change—Not reported—Not reported

MASH resolution without fibrosis worsening

Gatuzosiran
—Not reported
Rapirosiran (ALN-HSD)
—Not reported

Fibrosis stage, change

Gatuzosiran
—Not reported
Rapirosiran (ALN-HSD)
—Not reported

Liver fat (MRI-PDFF), change

Gatuzosiran
—Not reported
Rapirosiran (ALN-HSD)
—Not reported

ALT, change

Gatuzosiran
—Not reported
Rapirosiran (ALN-HSD)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Rapirosiran (ALN-HSD): no structured comparison results are available for MASH / NASH.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Gatuzosiran
Treatment-related TEAEs: 0/4 with ARO-HSD 25 mg, 0/4 with 50 mg, 1/4 with 100 mg, and 3/4 with 200 mg versus 0/16 with pooled placebo. NCT04202354 · Phase 1/2 · design grade: weak · reviewed ClinicalTrials.gov result
Predicted mean change from baseline in HSD17B13 protein expression at Week 28: -26.82% (25 mg), -61.82% (200 mg), -70.02% (400 mg), -75.27% (800 mg) NCT06104319 · Phase 2 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Gatuzosiran: 3 of 4 rows · Rapirosiran (ALN-HSD): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGatuzosiran
Dropout rate
0%200 mga
NCT04202354 · Phase 1/2 · monotherapy
show 6 more results
0%200 mg
NCT04202354 · Phase 1/2 · monotherapy
0%100 mg
NCT04202354 · Phase 1/2 · monotherapy
0%100 mg
NCT04202354 · Phase 1/2 · monotherapy
0%50 mg
NCT04202354 · Phase 1/2 · monotherapy
0%25 mg
NCT04202354 · Phase 1/2 · monotherapy
0%25 mg
NCT04202354 · Phase 1/2 · monotherapy
Discontinued due to AEs
—200 mga
NCT04202354 · Phase 1/2 · monotherapy
show 6 more results
—200 mg
NCT04202354 · Phase 1/2 · monotherapy
—100 mg
NCT04202354 · Phase 1/2 · monotherapy
—100 mg
NCT04202354 · Phase 1/2 · monotherapy
—50 mg
NCT04202354 · Phase 1/2 · monotherapy
—25 mg
NCT04202354 · Phase 1/2 · monotherapy
—25 mg
NCT04202354 · Phase 1/2 · monotherapy
Serious AEs
0%200 mga
NCT04202354 · Phase 1/2 · monotherapy
show 6 more results
16.7%200 mg
NCT04202354 · Phase 1/2 · monotherapy
0%100 mg
NCT04202354 · Phase 1/2 · monotherapy
0%100 mg
NCT04202354 · Phase 1/2 · monotherapy
0%50 mg
NCT04202354 · Phase 1/2 · monotherapy
0%25 mg
NCT04202354 · Phase 1/2 · monotherapy
0%25 mg
NCT04202354 · Phase 1/2 · monotherapy
Most frequent reported AEs
200 mga
injection site erythema 50% (placebo 0%)
injection site swelling 25% (placebo 0%)
mouth ulceration 25% (placebo 0%)
NCT04202354 · Phase 1/2 · monotherapy
show 6 more results
200 mg
arthralgia 16.7% (placebo 0%)
chest pain 16.7% (placebo 0%)
eye injury 16.7% (placebo 0%)
NCT04202354 · Phase 1/2 · monotherapy
100 mg
abdominal discomfort 25% (placebo 0%)
blepharospasm 25% (placebo 0%)
diarrhea 25% (placebo 0%)
NCT04202354 · Phase 1/2 · monotherapy
100 mg
blood creatine phosphokinase increased 16.7% (placebo 0%)
dermatitis contact 16.7% (placebo 0%)
headache 16.7% (placebo 0%)
NCT04202354 · Phase 1/2 · monotherapy
50 mg
medical device site reaction 25% (placebo 6.3%)
productive cough 25% (placebo 0%)
abdominal discomfort 0% (placebo 0%)
NCT04202354 · Phase 1/2 · monotherapy
25 mg
dental caries 25% (placebo 0%)
injection site bruising 25% (placebo 0%)
nausea 25% (placebo 0%)
NCT04202354 · Phase 1/2 · monotherapy
25 mg
arthralgia 16.7% (placebo 0%)
dental caries 16.7% (placebo 0%)
diarrhea 16.7% (placebo 0%)
NCT04202354 · Phase 1/2 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gatuzosiran's landscape · Rapirosiran (ALN-HSD)'s landscape